The Foundation for Sarcoidosis Research (FSR) is providing $200,000 in grants to fund research into improving the diagnosis and management of cardiac sarcoidosis. The funding comprises two grants specific to cardiac sarcoidosis, each totaling $100,000. This is double the investment the FSR made last year in…
News
Elevated blood levels of fatty molecules, or lipids — specifically triglycerides and low-density lipoprotein cholesterol (LDL-c), also known as bad cholesterol — may be linked with an increased risk of developing sarcoidosis, while certain lipid-lowering medications may help reduce the risk. That’s according to a study that looked at…
Employees in the U.S. who participate in clinical trials — including those testing treatments for sarcoidosis — and workers also caring for trial participants have access to Family and Medical Leave Act (FMLA) benefits. That’s according to a new letter from the U.S. Department of Labor, sent in response…
Among cardiac sarcoidosis (CS) patients treated with immunosuppressants, those with heart involvement alone can have poorer clinical outcomes than those whose sarcoidosis affects other organs along with the heart, according to a small study. Despite showing less heart inflammation before starting treatment, people with isolated CS (iCS) experienced higher…
Nearly 350 people joined a virtual public meeting that the Foundation for Sarcoidosis Research (FSR) ran as part of a U.S. Food and Drug Administration (FDA) program to discuss the unmet needs and challenges faced by those living with sarcoidosis. In the Externally Led Patient-Focused Drug Development meeting,…
Damage to and the loss of bile ducts, which are the tubes that carry the digestive fluid bile from the liver to the intestines, may be a sign of progressive liver disease among people with sarcoidosis, a study found. Such abnormalities appeared independent of inflammation related to granulomas, the…
Among people with sarcoidosis who failed to respond to earlier lines of treatment, the use of abatacept or tofacitinib — medications approved for other inflammatory conditions — appeared safe and effective, according to a Danish report. While neither abatacept (sold as Orencia in the U.S. and Europe) nor…
A study shows therapeutic doses of Atyr Pharma’s experimental therapy efzofitimod were associated with a lower rate of relapse in people with pulmonary sarcoidosis who were tapering oral corticosteroids, a mainstay treatment linked with toxic side effects when given for long periods and at high doses. While the…
A 26-year-old man in Nepal developed pulmonary sarcoidosis after a mild COVID-19 infection, per a new case report that suggests “sarcoidosis as a potential complication of COVID-19,” according to researchers. The man was initially diagnosed with post-COVID fibrosis, or thickening and scarring of lung tissue following a COVID-19 infection.
The activation of signaling pathways associated with immune B-cells may be a key feature that distinguishes sarcoidosis from tuberculosis, according to new research. Both conditions are characterized by the presence of granulomas, or small clumps of inflammatory cells, and can have similar clinical manifestations, such as uveitis, a type…
Recent Posts
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk
- When patients and caregivers swap roles, empathy usually follows
- Underdiagnosis of cardiac sarcoidosis leaves people at risk
- Repurposing drugs may improve survival for people with sarcoidosis
- Few with sarcoidosis see lung specialist within a year of diagnosis
- Overactive immune genes may fuel sarcoidosis inflammation: Study
- Drama series reflects the best, worst of online patient communities